Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Kura Oncology, Inc. has received a consensus rating of "Moderate Buy" from fifteen analysts, with ten recommending a buy and one a strong buy.
• The average twelve-month price target for Kura Oncology is $24.10, reflecting analysts' expectations for growth in the stock's value.
• Institutional investors have shown increased interest, with Tower Research Capital LLC significantly raising its position by 471.3% in the second quarter.

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $24.10.

A number of analysts have commented on the stock. Wall Street Zen raised shares of Kura Oncology from a "sell" rating to a "hold" rating in a research note on Sunday, August 17th. Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Mizuho reduced their target price on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, May 19th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a research report on Friday, June 20th. Finally, JMP Securities dropped their price target on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a research report on Monday, August 11th.

Institutional Trading of Kura Oncology

A number of hedge funds have recently made changes to their positions in KURA. Tower Research Capital LLC TRC grew its position in Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company's stock valued at $70,000 after purchasing an additional 9,958 shares in the last quarter. Rangeley Capital LLC acquired a new stake in shares of Kura Oncology during the 2nd quarter valued at $669,000. Man Group plc grew its holdings in shares of Kura Oncology by 234.7% during the 2nd quarter. Man Group plc now owns 522,388 shares of the company's stock valued at $3,014,000 after acquiring an additional 366,324 shares in the last quarter. EcoR1 Capital LLC increased its stake in shares of Kura Oncology by 59.1% in the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company's stock worth $24,234,000 after acquiring an additional 1,559,702 shares during the last quarter. Finally, Engineers Gate Manager LP raised its holdings in shares of Kura Oncology by 8.7% during the second quarter. Engineers Gate Manager LP now owns 62,564 shares of the company's stock worth $361,000 after acquiring an additional 5,028 shares in the last quarter.

Kura Oncology Stock Performance

Shares of NASDAQ KURA opened at $8.22 on Friday. The stock's fifty day simple moving average is $6.66 and its 200 day simple moving average is $6.58. The stock has a market capitalization of $713.50 million, a price-to-earnings ratio of -3.64 and a beta of 0.19. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $21.40.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. As a group, sell-side analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.